Mesothelioma medical therapy

Jump to navigation Jump to search

Mesothelioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mesothelioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Summary of Treatment for Pleural Mesothelioma

Summary of Treatment for Peritoneal Mesothelioma

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mesothelioma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mesothelioma medical therapy

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mesothelioma medical therapy

CDC on Mesothelioma medical therapy

Mesothelioma medical therapy in the news

Blogs on Mesothelioma medical therapy

Directions to Hospitals Treating Mesothelioma

Risk calculators and risk factors for Mesothelioma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

The treatment for mesothelioma depend on various factors, which include:[1]

  • Location of the mesothelioma
  • Stage
  • Resectability of the tumor
  • Type of symptoms
  • Overall health and performance status
  • Performance status
  • Age

The various treatment options for mesothelioma include:[1]

 
 
 
 
 
 
 
 
 
 
 
 
Treatment of Mesothelioma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supportive Care
 
Radiotherapy
 
Chemotherapy
 
Surgery

Supportive Care

Symptoms and signs Supportive Care
Loss of appetite Small amounts of high-calorie foods or fluids, having smaller, more frequent meals, and nutritional supplements can be helpful. Anti-emetic drugs can be used to control nausea and vomiting. Cold foods may be better tolerated and using plastic cutlery can help if foods have a metallic taste. When appropriate, medicines may be prescribed to help increase appetite. Cachexia can occur in people whose mesothelioma is very advanced.
Shortness of breath Pleural effusion is common with pleural mesothelioma, but can also occur with some peritoneal mesothelioma. Treatment options for pleural effusion may include:

Relaxation and breathing exercises may help with problems breathing. Oxygen therapy may be ordered to help relieve difficulty breathing.

Ascites Peritoneal mesothelioma can cause ascites. Paracentesis may be done to relieve symptoms. Another option is to insert catheter to drain the fluid from the abdomen.
Pain People with advanced mesothelioma may experience pain because the tumor grows into surrounding nerves and organs. The amount of pain often increases as the cancer advances. Pain may be managed by:
  • External beam radiation therapy: Palliative radiation therapy may help relieve pain by shrinking tumors that press on nerves or other organs.
  • Palliative surgery: Palliative surgery or procedures are not used to remove the tumor, but are done to relieve pain or other problems, such as pleural effusion or ascites. Palliative surgery or procedures may include:
  • Pain-relieving medications: Pain medications are used, especially for advanced mesothelioma.
T1 Iso- to hypointense solid component compared to adjacent brain
T1 Iso- to hypointense solid component compared to adjacent brain
T1 Iso- to hypointense solid component compared to adjacent brain
T2 Hyperintense solid component compared to adjacent brain

Radiation

For patients with localized disease, and who can tolerate a radical surgery, radiation is often given post-operatively as a consolidative treatment. The entire hemi-thorax is treated with radiation therapy, often given simultaneously with chemotherapy. This approach of using surgery followed by radiation with chemotherapy has been pioneered by the thoracic oncology team at Brigham & Women's Hospital in Boston. [2] Delivering radiation and chemotherapy after a radical surgery has led to extended life expectancy in selected patient populations with some patients surviving more than 5 years. As part of a curative approach to mesothelioma, radiotherapy is also commonly applied to the sites of chest drain insertion, in order to prevent growth of the tumor along the track in the chest wall.

Although mesothelioma is generally resistant to curative treatment with radiotherapy alone, palliative treatment regimens are sometimes used to relieve symptoms arising from tumor growth, such as obstruction of a major blood vessel. Radiation therapy when given alone with curative intent has never been shown to improve survival from mesothelioma. The necessary radiation dose to treat mesothelioma that has not been surgically removed would be very toxic.

Chemotherapy

In February 2004, the United States Food and Drug Administration approved pemetrexed (brand name Alimta) for treatment of malignant pleural mesothelioma. Pemetrexed is given in combination with cisplatin. Folic acid is also used to reduce the side-effects of pemetrexed.

Immunotherapy

Treatment regimens involving immunotherapy have yielded variable results. For example, intrapleural inoculation of Bacillus Calmette-Guérin (BCG) in an attempt to boost the immune response, was found to be of no benefit to the patient (while it may benefit patients with bladder cancer). Mesothelioma cells proved susceptible to in vitro lysis by LAK cells following activation by interleukin-2 (IL-2), but patients undergoing this particular therapy experienced major side effects. Indeed, this trial was suspended in view of the unacceptably high levels of IL-2 toxicity and the severity of side effects such as fever and cachexia. Nonetheless, other trials involving interferon alpha have proved more encouraging with 20% of patients experiencing a greater than 50% reduction in tumor mass combined with minimal side effects.

Heated Intraoperative Intraperitoneal Chemotherapy

A procedure known as heated intraoperative intraperitoneal chemotherapy was developed by Paul Sugarbaker at the Washington Cancer Institute.[2] The surgeon removes as much of the tumor as possible followed by the direct administration of a chemotherapy agent, heated to between 40 and 48°C, in the abdomen. The fluid is perfused for 60 to 120 minutes and then drained.

This technique permits the administration of high concentrations of selected drugs into the abdominal and pelvic surfaces. Heating the chemotherapy treatment increases the penetration of the drugs into tissues. Also, heating itself damages the malignant cells more than the normal cells.

References

  1. 1.0 1.1 Treatment of mesothelioma. Canadian cancer society 2016. http://www.cancer.ca/en/cancer-information/cancer-type/mesothelioma/treatment/?region=on. Accessed on February 8, 2016
  2. 2.0 2.1 "Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients." by D. Sugarbaker in J Thorac Cardiovasc Surg (1999) volume 117, pages 54-63 Template:Entrez Pubmed.


Template:WikiDoc Sources